Xi-chun Hu, M.D., Ph. D., is currently a Professor, Director of Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.
Dr. Hu has published more than 170 papers in the journals, such as Lancet Oncology, JCO and International Journal Cancer and 5 book chapters. He is vice editor of ABC (Advanced breast cancer) guideline (Chinese version) and one of the leading authors for CBCS (Chinese Breast Cancer Society) guideline for breast cancer diagnosis and treatment which is updated biannually.
Dr. Hu is an active member of the American Society of Clinical Oncology, General secretary & Member of the standing committee of CBCS (Chinese Breast Cancer Society), Vice chair of Shanghai Breast Cancer Society, Member of the Standing Academic Committee of CSCO (Chinese Society of Clinical Oncology). He is an editor of “International Journal of Biological Markers”, “Journal of Bone Oncology”, “China Oncology (Chin.)”, “World Clinical Drugs (Chin.)”, and a peer reviewer expert for “Oncotarget”, “Breast Cancer Research & Treatment”, “Disease Markers”, “Cancer letters”, “The Journal of Hematology & Oncology”, “Cancer Chemotherapy & Pharmacology”, etc. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, and graduate students.
Dr. Hu’s major interest is in the diagnosis and management of breast cancer, both in the clinic and in the laboratory, and phase I trial on new anticancer agents. His laboratory interests and contributions have been in the area of serum tumor markers, epigenetic alteration and gene expression, detection of residual disease. He and his laboratory are now concentrating on translational research on triple negative breast cancer and angiogenesis.